Article Text

Download PDFPDF

817 DT095895, a selective EP4 receptor antagonist with monotherapy efficacy in syngeneic mouse model(s) and best-in-class properties
  1. Anne-Laure Blayo1,
  2. Laurène Deshons1,
  3. Alexia Dumont1,
  4. Christel Franchet1,
  5. Célia Halter1,
  6. Ludovic Herbin1,
  7. Gaël Hommet1,
  8. Stanislas Mayer1,
  9. Alban Bessede2,
  10. Imane Nafia2,
  11. Marjorie Sidhoum1,
  12. Xavier Leroy1 and
  13. Stéphan Schann1
  1. 1Domain Therapeutics, Illkirch, France
  2. 2Explicyte Immuno-Oncology, Bordeaux, France


Background Elevated levels of Prostaglandin E2 (PGE2), an eicosanoid notably synthesized by the cyclooxygenase-2 (COX-2), exert strong immunosuppressive effects in the tumor microenvironment. COX-2-positive solid tumors have the ability to use this pathway as a resistance mechanism, especially to escape from the host immune system, thus limiting the anti-tumor effects of immune checkpoint inhibitors (ICI). These immunosuppressive effects are largely mediated by the EP4 receptor, expressed on multiple immune cells.

Methods A novel series of EP4 receptor antagonists has been developed, with improved pharmacokinetic properties when compared to the EP4 receptor antagonists currently being evaluated in clinical trials. An intensive lead optimization program led to the identification of DT095895, a small molecule development candidate with a ‘best-in class’ potential. DT095895 was assessed in multiple syngeneic mouse tumor models selected for their COX-2 expression profile.

Results DT095895 preclinical package will be presented in the poster. Efficacy was seen both in a monotherapy setting, as well as in combination with an ICI. Additionally, a specific biomarker program was implemented and validated in order to show target engagement. A phospho-flow murine whole blood assay was set-up to assess the ability of DT095895 to inhibit CREB phosphorylation induced by a selective EP4 receptor agonist in CD3+ cells. This biomarker was further developed for human whole blood to support Phase 1 and clinical trials studies.

Conclusions DT095895 is a selective EP4 receptor antagonist and demonstrates strong anti-tumor effects in multiple syngeneic mouse tumor models, both as a monotherapy and in combination with ICI, through the inhibition of the PGE2-induced immunosuppression. DT095895 progresses in regulatory development.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.